TrkC receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “TrkC receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in TrkC receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TrkC receptor antagonists: Overview
Trk receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. Trk receptors affect neuronal survival and differentiation through several signaling cascades. However, the activation of these receptors also has significant effects on functional properties of neurons. TrkC is ordinarily activated by binding with NT-3 and has little activation by other ligands. (TrkA and TrkB also bind NT-3, but to a lesser extent).TrkC is mostly expressed by proprioceptive sensory neurons. The axons of these proprioceptive sensory neurons are much thicker than those of nociceptive sensory neurons, which express trkA.
Report Highlights
This segment of the TrkC receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TrkC receptor antagonists Emerging Drugs
Further product details are provided in the report……..
TrkC receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different TrkC receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
TrkC receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TrkC receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TrkC receptor antagonists drugs.
TrkC receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TrkC receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in TrkC receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TrkC receptor antagonists: Overview
Trk receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. Trk receptors affect neuronal survival and differentiation through several signaling cascades. However, the activation of these receptors also has significant effects on functional properties of neurons. TrkC is ordinarily activated by binding with NT-3 and has little activation by other ligands. (TrkA and TrkB also bind NT-3, but to a lesser extent).TrkC is mostly expressed by proprioceptive sensory neurons. The axons of these proprioceptive sensory neurons are much thicker than those of nociceptive sensory neurons, which express trkA.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TrkC receptor antagonists R&D. The therapies under development are focused on novel approaches for TrkC receptor antagonists.
This segment of the TrkC receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TrkC receptor antagonists Emerging Drugs
- Ensartinib: Betta Pharmaceuticals
- Repotrectinib: Turning Point Therapeutics
Further product details are provided in the report……..
TrkC receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different TrkC receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TrkC receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TrkC receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TrkC receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TrkC receptor antagonists drugs.
TrkC receptor antagonists Report Insights
- TrkC receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TrkC receptor antagonists drugs?
- How many TrkC receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TrkC receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TrkC receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TrkC receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Betta Pharmaceuticals
- Turning Point Therapeutics
- AnHeart Therapeutics
- Roche
- Pyramid Biosciences
- Chia Tai Tianqing Pharmaceutical Group
- Jiangsu Carephar Pharmaceutical
- Bayer
- Plexxikon
- Ensartinib
- Repotrectinib
- Taletrectinib
- Entrectinib
- PBI 200
- TQB 3558
- KFP H013
- Larotrectinib
- PLX 7486
Introduction
Executive Summary
TrkC receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TrkC receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Repotrectinib: Turning Point Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Entrectinib: Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
PBI 200: Pyramid Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
KFP H013: Jiangsu Carephar Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TrkC receptor antagonists Key Companies
TrkC receptor antagonists Key Products
TrkC receptor antagonists- Unmet Needs
TrkC receptor antagonists- Market Drivers and Barriers
TrkC receptor antagonists- Future Perspectives and Conclusion
TrkC receptor antagonists Analyst Views
TrkC receptor antagonists Key Companies
Appendix
Executive Summary
TrkC receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TrkC receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Repotrectinib: Turning Point Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Entrectinib: Roche
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
PBI 200: Pyramid Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
KFP H013: Jiangsu Carephar Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TrkC receptor antagonists Key Companies
TrkC receptor antagonists Key Products
TrkC receptor antagonists- Unmet Needs
TrkC receptor antagonists- Market Drivers and Barriers
TrkC receptor antagonists- Future Perspectives and Conclusion
TrkC receptor antagonists Analyst Views
TrkC receptor antagonists Key Companies
Appendix